English, PDF, 175kb
Many policy initiatives have been implemented in Indonesia, in recognition of the key role quality plays in strengthening health care systems.
English, PDF, 183kb
Many policy initiatives have been implemented in China, in recognition of the key role quality plays in strengthening health care systems.
English, PDF, 194kb
Many policy initiatives have been implemented in India, in recognition of the key role quality plays in strengthening health care systems. Accreditation programmes for hospitals and health care providers and the development of hospital infection control programmes seem to be the most relevant initiatives.
English, PDF, 130kb
English, PDF, 88kb
Highest life expectancy in Japan has been attained through a series of public health actions and universal health coverage.
Countries in the Asia/Pacific region need to step up their efforts to give more people access to affordable, quality health care. Too many people, especially women, cannot get the medical treatment they need due to high costs, difficulties in getting permission to see a doctor or a lack of health care providers in rural areas, according to a new OECD report.
English, PDF, 192kb
Many policy initiatives have been implemented in Thailand, in recognition of the key role quality plays in strengthening health care systems.
This third edition of Health at a Glance Asia/Pacific presents a set of key indicators of health status, the determinants of health, health care resources and utilisation, health care expenditure and financing and health care quality across 27 Asia/Pacific countries and economies. Drawing on a wide range of data sources, it builds on the format used in previous editions of Health at a Glance, and gives readers a better understanding of the factors that affect the health of populations and the performance of health systems in these countries and economies.
Each of the indicators is presented in a user-friendly format, consisting of charts illustrating variations across countries and over time, brief descriptive analyses highlighting the major findings conveyed by the data, and a methodological box on the definition of the indicator and any limitations in data comparability. An annex provides additional information on the demographic context in which health systems operate. It is a joint OECD and WHO/WPRO and WHO/SEARO publication.
Turkey underwent a very ambitious reform programme in 2003, the so-called "Health Transformation Programme". Access to healthcare in Turkey has greatly increased with the attainment of Universal Health Coverage, as also demonstrated by improvement in health outcomes, most notably around maternal and child health and infectious diseases. However, despite these significant achievements, Turkey has a significant way to travel to deliver high-quality health services to its population. Governance of the health system is highly centralised and typified by directive control from the Ministry of Health, and information collected in different part of the system is not always fully exploited.
The OECD Review of Health Care Quality in Turkey recommends a number of changes to address these shortcomings. The key recommendations are that: i) Turkey needs to develop robust systems to standardise and monitor the quality of care, encourage continuous professional development and incorporate patient views; ii) some loosening of the governance structure would be welcome, to allow regions greater flexibility to assess and respond to local health needs and to continue to provide health workers with incentives for improve quality; iii) data on health sector activity and outcomes need to be made more available and more usable for individual patients and clinicians, while greater effort is needed to increase the robustness of Turkey’s information systems at national level and harmonise performance measures to OECD and other international comparators.
English, PDF, 478kb
This country profile describes in details the Canadian pharmaceutical system, including decision-making processes for regulatory approval, reimbursement and pricing; assessment guidelines; institution and stakeholders involved and specific policies for new high cost drugs, when available.